Agfa names new Impax sales team
Agfa names new Impax sales teamAgfa continues to solidify the integration of Sterling Diagnostic Imaging assets into its PACS and conventional imaging businesses (PNN 8/99). Most recently, the PACS and film giant revamped its sales
Agfa names new Impax sales team
Agfa continues to solidify the integration of Sterling Diagnostic Imaging assets into its PACS and conventional imaging businesses (
PNN
8/99). Most recently, the PACS and film giant revamped its sales organization, separating the Impax digital image management and computed radiography business functions from its conventional imaging and hard-copy systems sales. Agfa also announced several key appointments to its sales teams.
John Scarano will now head up the Impax North American sales force. Those reporting to Scarano include John DeSantis, who previously directed Agfas military radiology sales and will now be responsible for Impax sales to the government; Andrea Harding, who had been responsible for western region PACS sales at Sterling and will now manage commercial Impax sales in the central and western regions; and Anthony Passarello, who was Agfas director of southeastern regional sales and will now lead Impax sales for the commercial market in the northeast and southern regions.
In the new Imaging Systems group, Bruce Gower will handle sales in the corporate healthcare sector. He was previously with Sterling as zone general manager.
- Search again
- Homepage
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
